Literature DB >> 16331804

Cancer screening in patients with systemic lupus erythematosus.

Sasha R Bernatsky1, Glinda S Cooper, Chris Mill, Rosalind Ramsey-Goldman, Ann E Clarke, Christian A Pineau.   

Abstract

OBJECTIVE: To examine whether patients with systemic lupus erythematosus (SLE) undergo cancer screening according to established guidelines, to compare their reported screening practices with information from the general population, and to examine potential predictors of screening within our SLE sample.
METHODS: We conducted a patient survey of cancer screening practices within the Montreal General Hospital lupus cohort. We compared self-reported frequency of cancer screening to guidelines suggested for the general population, and to figures for cancer screening reported in the general population. We also developed logistic regression models to establish potential predictors of screening for patients with SLE, with cervical cancer screening being the outcome of interest in our primary analyses.
RESULTS: Of 48 women aged 50-69, 53% (95% confidence interval, CI: 38-68) had had a mammogram in the past 12 months, compared to 74% (95% CI: 73-75) for similarly aged Quebec women. Of 51 subjects aged 50 and older, only 18% (95% CI: 8-34) reported screening (fecal occult blood check with or without endoscopy) within the recommended time frame, compared to 48% (95% CI: 45-51) for colorectal screening for persons > 50 in the general population. Only 9 of 27 patients with SLE aged less than 30 had Pap tests in the past 12 months (33%, 95% CI: 19-52), compared with a general population rate of 56% (95% CI: 53-59) for similarly aged Quebec women. Our logistic regression model suggested that, among the SLE patients, non-whites, those with lower education, and those with higher disease damage scores were less likely to undergo cervical Pap testing.
CONCLUSION: These data suggest that appropriate cancer screening may be overlooked in patients with SLE.

Entities:  

Mesh:

Year:  2005        PMID: 16331804

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  21 in total

1.  Cancer risk in systemic lupus: an updated international multi-centre cohort study.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Jeremy Labrecque; Lawrence Joseph; Jean-Francois Boivin; Michelle Petri; Asad Zoma; Susan Manzi; Murray B Urowitz; Dafna Gladman; Paul R Fortin; Ellen Ginzler; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Steven Edworthy; Soren Jacobsen; Caroline Gordon; Mary Anne Dooley; Christine A Peschken; John G Hanly; Graciela S Alarcón; Ola Nived; Guillermo Ruiz-Irastorza; David Isenberg; Anisur Rahman; Torsten Witte; Cynthia Aranow; Diane L Kamen; Kristjan Steinsson; Anca Askanase; Susan Barr; Lindsey A Criswell; Gunnar Sturfelt; Neha M Patel; Jean-Luc Senécal; Michel Zummer; Janet E Pope; Stephanie Ensworth; Hani El-Gabalawy; Timothy McCarthy; Lene Dreyer; John Sibley; Yvan St Pierre; Ann E Clarke
Journal:  J Autoimmun       Date:  2013-02-12       Impact factor: 7.094

2.  Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention.

Authors:  Seoyoung C Kim; Sarah Feldman; Anna-Barbara Moscicki
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

3.  Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study.

Authors:  Shir Azrielant; Shmuel Tiosano; Abdulla Watad; Naim Mahroum; Aaron Whitby; Doron Comaneshter; Arnon D Cohen; Howard Amital
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

Review 4.  Prostate cancer in systemic lupus erythematosus.

Authors:  S Bernatsky; R Ramsey-Goldman; C Gordon; A E Clarke
Journal:  Int J Cancer       Date:  2011-03-29       Impact factor: 7.396

Review 5.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

6.  [Managing comorbidities of inflammatory rheumatic diseases].

Authors:  K de Groot; E Märker-Hermann
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

7.  Cervical neoplasia in systemic lupus erythematosus: a nationwide study.

Authors:  Hjalmar Wadström; Elizabeth V Arkema; Christopher Sjöwall; Johan Askling; Julia F Simard
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

8.  Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2008-04-02       Impact factor: 2.506

9.  European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies.

Authors:  M Mosca; C Tani; M Aringer; S Bombardieri; D Boumpas; R Brey; R Cervera; A Doria; D Jayne; M A Khamashta; A Kuhn; C Gordon; M Petri; O P Rekvig; M Schneider; Y Sherer; Y Shoenfeld; J S Smolen; R Talarico; A Tincani; R F van Vollenhoven; M M Ward; V P Werth; L Carmona
Journal:  Ann Rheum Dis       Date:  2009-11-05       Impact factor: 19.103

Review 10.  Malignancies in systemic lupus erythematosus.

Authors:  Emese Kiss; Laszlo Kovacs; Peter Szodoray
Journal:  Autoimmun Rev       Date:  2009-07-27       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.